-
公开(公告)号:US08431130B2
公开(公告)日:2013-04-30
申请号:US12843740
申请日:2010-07-26
申请人: Tariq Ghayur , Boris Labkovsky , Jeffrey W. Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Singh Kang , Brad Hedberg
发明人: Tariq Ghayur , Boris Labkovsky , Jeffrey W. Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Singh Kang , Brad Hedberg
IPC分类号: A61K39/395 , C07K16/18 , C07K16/24 , C12P21/08
CPC分类号: C07K16/244 , A61K2039/505 , C07H21/04 , C07K2317/21
摘要: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
摘要翻译: 本发明包括IL-18结合蛋白,特别是结合人白细胞介素-18(hIL-18)的抗体。 具体地,本发明涉及完全是人抗体的抗体。 优选的抗体对hIL-18具有高亲和力和/或在体外和体内中和hIL-18活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性,例如在患有hIL-18活性有害的病症的人类受试者中。
-
公开(公告)号:US07968684B2
公开(公告)日:2011-06-28
申请号:US10988360
申请日:2004-11-12
申请人: Tariq Ghayur , Boris Labkovsky , Jeffrey W. Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Singh Kang , Brad Hedberg
发明人: Tariq Ghayur , Boris Labkovsky , Jeffrey W. Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Singh Kang , Brad Hedberg
IPC分类号: C07K16/00 , A61K39/395 , C12N1/11 , C12N1/15 , C12N1/21 , C12N5/04 , C12N5/07 , C12N15/09 , C12N15/11 , C12N15/13 , C12N15/63
CPC分类号: C07K16/244 , A61K2039/505 , C07H21/04 , C07K2317/21
摘要: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
摘要翻译: 本发明包括IL-18结合蛋白,特别是结合人白细胞介素-18(hIL-18)的抗体。 具体地,本发明涉及完全是人抗体的抗体。 优选的抗体对hIL-18具有高亲和力和/或在体外和体内中和hIL-18活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性,例如在患有hIL-18活性有害的病症的人类受试者中。
-
公开(公告)号:US20100291088A1
公开(公告)日:2010-11-18
申请号:US12843740
申请日:2010-07-26
申请人: Tariq Ghayur , Boris Labkovsky , Jeffrey W. Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Singh Kang , Brad Hedberg
发明人: Tariq Ghayur , Boris Labkovsky , Jeffrey W. Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Singh Kang , Brad Hedberg
IPC分类号: A61K39/395 , C07H21/04 , C12N15/63 , C12N1/00 , C12N1/21 , C12N5/10 , C12N1/15 , C12N1/19 , C12P21/02 , A61K38/17 , C07K16/24 , A61P29/00
CPC分类号: C07K16/244 , A61K2039/505 , C07H21/04 , C07K2317/21
摘要: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
摘要翻译: 本发明包括IL-18结合蛋白,特别是结合人白细胞介素-18(hIL-18)的抗体。 具体地,本发明涉及完全是人抗体的抗体。 优选的抗体对hIL-18具有高亲和力和/或在体外和体内中和hIL-18活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性,例如在患有hIL-18活性有害的病症的人类受试者中。
-
公开(公告)号:US20050147610A1
公开(公告)日:2005-07-07
申请号:US10988360
申请日:2004-11-12
申请人: Tariq Ghayur , Boris Labkovsky , Jeffrey Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Kang , Brad Hedberg
发明人: Tariq Ghayur , Boris Labkovsky , Jeffrey Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Kang , Brad Hedberg
IPC分类号: A61K39/395 , C07H21/04 , C07K16/24 , C12N5/06 , C12P21/04
CPC分类号: C07K16/244 , A61K2039/505 , C07H21/04 , C07K2317/21
摘要: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
摘要翻译: 本发明包括IL-18结合蛋白,特别是结合人白细胞介素-18(hIL-18)的抗体。 具体地,本发明涉及完全是人抗体的抗体。 优选的抗体对hIL-18具有高亲和力和/或在体外和体内中和hIL-18活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性,例如在患有hIL-18活性有害的病症的人类受试者中。
-
公开(公告)号:US20050100965A1
公开(公告)日:2005-05-12
申请号:US10706689
申请日:2003-11-12
申请人: Tariq Ghayur , Boris Labkovsky , Jeffrey Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Kang , Brad Hedberg
发明人: Tariq Ghayur , Boris Labkovsky , Jeffrey Voss , Larry Green , John Babcook , Xiao-chi Jia , James Wieler , Jaspal Kang , Brad Hedberg
CPC分类号: G01N33/6869 , A61K2039/505 , C07K16/244 , C07K2317/33 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , Y02A50/407
摘要: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
6.
公开(公告)号:US08309093B2
公开(公告)日:2012-11-13
申请号:US12718902
申请日:2010-03-05
申请人: Jean Gudas , Aya Jakobovits , Zili An , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Xiao-chi Jia , Dennis Benjamin , Ruth Moser , Peter Senter
发明人: Jean Gudas , Aya Jakobovits , Zili An , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Xiao-chi Jia , Dennis Benjamin , Ruth Moser , Peter Senter
IPC分类号: A61K39/395
CPC分类号: C07K16/30 , A61K45/06 , A61K47/6803 , A61K47/6851 , A61K47/6863 , A61K2039/505 , C07K16/3046
摘要: Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
摘要翻译: 本文描述了结合24P4C12蛋白及其变体的抗体药物偶联物(ADC)。 24P4C12在正常成人组织中表现出组织特异性表达,并且在表I中列出的癌症中异常表达。因此,本发明的ADC提供了用于治疗癌症的治疗组合物。
-
公开(公告)号:US08039597B2
公开(公告)日:2011-10-18
申请号:US12205560
申请日:2008-09-05
申请人: Arthur B. Raitano , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Steven B. Kanner , Pia M. Challita-Eid , Xiao-chi Jia , Jean Gudas , Aya Jakobovits
发明人: Arthur B. Raitano , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Steven B. Kanner , Pia M. Challita-Eid , Xiao-chi Jia , Jean Gudas , Aya Jakobovits
CPC分类号: A61K51/1051 , A61K39/00 , A61K39/0011 , A61K47/6809 , A61K47/6821 , A61K47/6823 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6869 , A61K49/0013 , A61K51/1054 , A61K51/1057 , A61K51/1072 , A61K2039/505 , A61K2039/5152 , C07K14/47 , C07K14/4748 , C07K16/303 , C07K16/3069 , C07K2317/21 , C07K2317/56 , C07K2317/732 , C07K2317/77 , G01N33/57484 , G01N2500/00
摘要: Antibodies and molecules derived therefrom that bind to 24P4C12 protein and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
摘要翻译: 其中24P4C12在正常成人组织中表现出组织特异性表达,并且在表I中列出的癌症中异常表达。因此,24P4C12提供诊断,预后,预防和预后, /或癌症治疗靶标。 24P4C12基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与24P4C12反应的抗体或T细胞可用于主动或被动免疫。
-
8.
公开(公告)号:US20100330107A1
公开(公告)日:2010-12-30
申请号:US12718902
申请日:2010-03-05
申请人: Jean Gudas , Aya Jakobovits , Zili An , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Xiao-chi Jia , Dennis Benjamin , Ruth Moser , Peter Senter
发明人: Jean Gudas , Aya Jakobovits , Zili An , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Xiao-chi Jia , Dennis Benjamin , Ruth Moser , Peter Senter
IPC分类号: A61K39/395 , C07K16/00 , A61P35/00
CPC分类号: C07K16/30 , A61K45/06 , A61K47/6803 , A61K47/6851 , A61K47/6863 , A61K2039/505 , C07K16/3046
摘要: Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
摘要翻译: 本文描述了结合24P4C12蛋白及其变体的抗体药物偶联物(ADC)。 24P4C12在正常成人组织中表现出组织特异性表达,并且在表I中列出的癌症中异常表达。因此,本发明的ADC提供了用于治疗癌症的治疗组合物。
-
9.
公开(公告)号:US07811565B2
公开(公告)日:2010-10-12
申请号:US12433760
申请日:2009-04-30
申请人: Aya Jakobovits , Steven B. Kanner , Pia M. Challita-Eid , Juan J. Perez-Villar , Daulet Satpaev , Arthur B. Raitano , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Xiao-chi Jia , Jean Gudas
发明人: Aya Jakobovits , Steven B. Kanner , Pia M. Challita-Eid , Juan J. Perez-Villar , Daulet Satpaev , Arthur B. Raitano , Robert Kendall Morrison , Karen Jane Meyrick Morrison , Xiao-chi Jia , Jean Gudas
IPC分类号: A16K39/395 , G01N33/574 , C07K16/30
CPC分类号: C07K16/30 , A61K2039/505 , C07K2317/24 , C07K2317/73
摘要: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
摘要翻译: 其中161P2F10B在正常成人组织中表现出组织特异性表达,并且在表I所示的癌症中异常表达。因此,161P2F10B提供诊断,预后,预防和 /或癌症治疗靶标。 161P2F10B基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与161P2F10B反应的抗体或T细胞可用于主动或被动免疫。
-
10.
公开(公告)号:US20100047166A1
公开(公告)日:2010-02-25
申请号:US12544973
申请日:2009-08-20
申请人: Steven B. KANNER , Aya Jakobovits , Jean Gudas , Arthur B. Raitano , Robert Kendall Morrison , Pia M. Challita-Eid , Xiao-chi Jia
发明人: Steven B. KANNER , Aya Jakobovits , Jean Gudas , Arthur B. Raitano , Robert Kendall Morrison , Pia M. Challita-Eid , Xiao-chi Jia
IPC分类号: A61K39/395 , C07K16/00 , A01K67/027 , C12N5/12 , C07H21/04 , C12N15/63 , C12N5/10 , C12P21/02 , G01N33/53 , A61K51/10 , C12Q1/68 , A61P35/00
CPC分类号: G01N33/57484 , A01K2267/0331 , A61K47/6807 , A61K47/6851 , A61K51/1045 , A61K2039/505 , C07K16/2803 , C07K16/30 , C07K2317/21 , C07K2317/34 , C07K2317/54 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , G01N2500/04
摘要: Antibodies and molecules derived therefrom that bind to 58P1D12 protein and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 58P1D12 can be used in active or passive immunization.
摘要翻译: 其中58P1D12在正常成人组织中表现出组织特异性表达,并且在表I中列出的癌症异常表达。因此,58P1D12提供诊断,预后,预防和预后 /或癌症治疗靶标。 58P1D12基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与58P1D12反应的抗体或T细胞可用于主动或被动免疫。
-
-
-
-
-
-
-
-
-